Pfizer says study shows RSV vaccine had an 82% efficacy rate for infants up to 90 days old and 69% by 6 months
Pfizer announced the development of an experimental vaccine to be given to pregnant women to protect babies from serious illness.
The pharmaceutical company announced in a statement that the vaccine was effective in protecting infants and mothers from respiratory syncytial virus, or RSV, in Phase 3 of the company’s study.
Pfizer seeks approval for Omicron booster for children over the age of 5
Administered during pregnancy, the vaccine demonstrated an efficacy at approximately 82% from birth to the first 90 days of life; Later, efficacy decreased to about 69% for the first six months of life. Overall, the mothers and their infants received the vaccine well and showed no evidence for cause for concern for safety.
|anchor||Security||The last||Change||Change %|
Pfizer CEO Albert Boerla tests positive for COVID-19 for the second time in less than 2 months
“These data reinforce Pfizer’s resolve to bring our expertise in research and development of innovative vaccines to meet critical public health needs using new approaches and technologies. We look forward to bringing this vaccine candidate to expectant mothers.” We look forward to working with the FDA and other regulatory agencies to help protect our infants from severe RSV during the most vulnerable first six months of life, in which infants carry the highest burden of RSV disease. would like to thank the pregnant women who volunteered for this trial, along with their infants, and thank all the investigators from around the world who participated in the study for their contributions to this landmark research,” in a statement Tuesday. Annalisa Anderson, senior vice president and chief scientific officer for vaccine research and development at Pfizer.
Pfizer says it is considering a list price of $110 to $130 for a COVID-19 vaccine in the US
The study’s findings have not yet been published in any academic peer-reviewed journal.
Pfizer intends to submit a biologics license application to the US Food and Drug Administration by the end of 2022. If approved, it would be the first maternal vaccine to protect infants from the deadly respiratory disease.
Get Fox Business on the go by clicking here
Credit: www.foxbusiness.com /